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Abstract

Comparison of Quality of Life in Diabetics Using Insulin Injection Therapy versus
Subcutaneous Insulin Infusion Therapy
The goal of this study was to determine the effectiveness of insulin delivered via multiple
injections or by infusion via a pump on the quality of life in adult insulin-dependent diabetics.
Four parameters, namely hemoglobin A1C (3 month average blood sugar levels), self-reported
healthy eating habits demonstrated by consumption of 3 meals/3 snacks everyday, frequency of
exercise of daily 30 min or longer duration and opinion of quality of life, were evaluated in
patients receiving either insulin injections or infusion.
Pump users reported enhanced eating and exercise behaviors and feeling in good health,
compared with patients receiving injections. In contrast, hemoglobin A1C was lower (6.9 + 0.9
%) in patients receiving insulin injections compared with those receiving infusions (7.9 + 0.6 %).
Pump wearers perceived that they had a better quality of life, but their glycemic control was not
necessarily improved compared to those on insulin injections.
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Chapter 1
Introduction and Research Statement
Introduction
Aretaeus was a Greek physician from Cappadocia who practiced in Rome and
Alexandria in 100 A.D. Aretaeus was completely forgotten after his death until around 1554
when his manuscripts, On the Causes and Indications of Acute and Chronic Diseases and On the
Treatment of Acute and Chronic Diseases, were discovered. Both were written in Ionic Greek dialect
and contained model descriptions of pleurisy, diphtheria, tetanus, pneumonia, asthma, and
epilepsy but also show that he was the first to distinguish between spinal and cerebral paralyses.
Aretaeus was the first to name and clearly describe the condition of diabetes, which is Greek for
“siphon,” indicative of the diabetic’s intense thirst and excessive emission of fluids, and rendered
the earliest clear account of that disease now known (Encyclopedia Britannica Online).
In 1889, two medical researchers in Europe, J. von Mering and O. Minowski, removed
the pancreas of a dog to see what would happen. The dog began to urinate a lot, and the
researchers noticed there were flies swarming around the pools of urine. When they tested the
urine and discovered that it contained sugar, they realized the dog had developed diabetes. Now
they knew that diabetes was a disease of the pancreas (Bliss, 1982).
Until this century, the only way doctors had to treat diabetes was through diet. Aretaeus
of Cappadocia prescribed a diet of milk, gruel, cereal, and wine. Other doctors throughout
history tried a strict meat diet, and still others ordered a diet high in fat. These diets didn’t help,
of course. People who developed Type 1 diabetes typically survived only a few months (Bliss,
1982). Type 1 is a form of diabetes that usually develops during childhood or adolescence and is

characterized by a severe deficiency of insulin secretion resulting from atrophy of the Islets of
Langerhans and causing hyperglycemia (high blood sugar) (Webster’s Dictionary Online).
Then, in 1921, in Toronto, Ontario, Canada, Dr. Frederick G. Banting and a medical
student, Charles H. Best, took fluid from animal pancreases, purified it, and injected it into
Leonard Thompson, an 11-year-old boy suffering from severe diabetes. Leonard was barely alive
and weighed only 75 pounds. After injections of this purified fluid, later to be established as
insulin, his blood sugar levels went down, he was able to eat a more normal diet, gained weight,
and lived to be an adult (Bliss, 1982). Banting and Best shared the Nobel Peace Prize of
Medicine for their discovery of insulin.
Since 1971, scientists have been trying to create an artificial pancreas to try to cure
diabetes. With an artificial pancreas, a person with diabetes could control blood sugar levels
without injecting insulin (Bliss, 1982).
Definition of Terms
The following definitions apply to the terms used in this research study:
Carbohydrate Counting: An effective way to control insulin regimens by means of giving only
enough insulin to cover the grams of carbohydrate ingested.
Diabetes: A disorder of carbohydrate metabolism, usually occurring in genetically predisposed
individuals, characterized by inadequate production or utilization of insulin and resulting in
excessive amounts of glucose in the blood and urine, excessive thirst, weight loss, and, in some
cases, progressive destruction of small blood vessels leading to such complications as infections
and gangrene of the limbs or blindness (Webster’s Dictionary Online).
Diabetic Ketoacidosis: High blood glucose with the presence of ketones in the urine and
bloodstream, often caused by taking too little insulin to treat diabetes or during illness (ADA
Online, 2007).
Glycemic: Literally, “causing glucose (sugar) in the blood.” Blood glucose is closely related to the
amount and type of carbohydrates consumed (Webster’s Dictionary Online).
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Hemoglobin A1C: A1C, also known as glycated hemoglobin or glycosylated hemoglobin,
indicates a patient’s blood sugar control over the last 2-3 months. A1C is formed when glucose
in the blood binds irreversibly to hemoglobin to form a stable glycated hemoglobin complex.
Since the normal life span of red blood cells is 90-120 days, the A1C will only be eliminated
when the red cells are replaced (Diabetes Care, 2002).
Hyperglycemia: The presence of an abnormally high concentration of glucose in the blood
(Webster’s Dictionary Online).
Hypoglycemia: The presence of abnormally low concentrations of glucose in the blood
(Webster’s Dictionary Online).
Insulin Analogs: These are versions of insulin that have been altered to achieve greater control
over blood glucose levels (JDRF, 2007).
Insulin Glargine: Once injected, glargine forms a precipitate which is absorbed very slowly and
evenly into the bloodstream lasting for almost 24 hours (JDRF, 2007).
Insulin Pump: An external battery-powered device that injects insulin into the body at a
programmed rate to control blood sugars (Webster’s Dictionary Online).
Quality of Life: A personal perception of health and well-being and how it affects daily life and
activities.
Subcutaneous: Located or placed just beneath the skin (Webster’s Dictionary Online).
Type 1 Diabetes: Diabetes of a form that usually develops during childhood or adolescence and
is characterized by a severe deficiency of insulin secretion resulting from atrophy of the Islets of
Langerhans and causing hyperglycemia and a marked tendency toward ketoacidosis called also
insulin-dependent diabetes, insulin-dependent diabetes mellitus, juvenile diabetes, juvenile-onset diabetes, type 1
diabetes mellitus (Webster’s Dictionary Online).
Type 2 Diabetes: Diabetes mellitus of a common form that develops especially in adults and
most often in obese individuals, which is characterized by hyperglycemia resulting from impaired
insulin utilization coupled with the body’s inability to compensate with increased insulin
production, called also adult-onset diabetes, late-onset diabetes, maturity-onset diabetes, non-insulin-dependent
diabetes, non-insulin-dependent diabetes mellitus, type 2 diabetes mellitus (Webster’s Dictionary Online).

3

Research Statement
The goal of this study was to determine whether continuous subcutaneous insulin
infusion is a better way of controlling diabetes than multiple insulin injections. Continuous
subcutaneous insulin infusion (CSII) therapy has multiple potential advantages over injection
therapy, including an enhanced ability to mimic physiologic insulin release as well as permitting
greater flexibility in food intake and physical activity (Pickup, Keen, 2002).
Independent and Dependent Variables
To investigate the research question, a retrospective cohort study design was used with
multiple insulin injections being the control group and intensive insulin pump therapy being the
experimental group.
Independent Variable

Dependent Variable

Hemoglobin A1C level on Insulin Pump

< 7% (Recommended) (Diabetes
Care, 2002)

Hemoglobin A1C level on Insulin Injections

< 7% (Recommended) (Diabetes
Care, 2002)

Diet on Insulin Pump

3 meals and snacks daily
(Recommended) (Rosenstock, et
al, 2000)

Diet on Insulin Injections

3 meals and snacks daily
(Recommended) (Rosenstock et
al, 2000)

Exercise on Insulin Pump

3 days /week for 30 minutes
(Recommended) (Medline Plus,
2004)

Exercise on Insulin Injections

3 days / week for 30 minutes
(Recommended) (Medline Plus,
2004)
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Opinion of Quality of Life
The outcome measures evaluated are hemoglobin A1C levels, ingestion of consistent
meals, frequency of exercise, and the subjects’ opinion of their quality of life. The quality of life
in uncontrolled diabetics is diminished with complications such as blindness, kidney failure,
heart disease, and amputations.
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Chapter 2
Review of Literature
Complications with Uncontrolled Diabetes
Living with diabetes in the 21st century is a fortunate situation for most diabetics. An
insulin pump helps to greatly reduce the risk of future complications associated with
uncontrolled diabetes mellitus. But what exactly are the complications with uncontrolled
diabetes?
Hyperglycemia or high blood sugar seems to affect the body’s small blood vessels and
the nervous system. Over time, high glucose levels change the walls of small blood vessels,
causing them to thicken and leak. The vessels may eventually clog, impeding blood flow to vital
organs. This clogging or impedance of blood flow may lead to eye disease or retinopathy, nerve
damage or neuropathy, kidney disease or nephropathy, and cardiovascular disease (Nathan,
2004).
Scientists don’t know what causes retinopathy, but they do know it occurs in two stages.
In the first stage, the walls of the small blood vessels become abnormal and weaken. They leak
fluid into surrounding tissue, leaving deposits of protein and fat called hard exudates. The
vessels also develop micro-aneurysms, tiny bulges or pockets in their walls that tend to leak red
blood cells into the retina. As the condition progresses, the abnormal vessels begin to close,
robbing the retina of its blood supply. Nerve fibers die off due to poor circulation and lack of
oxygen, creating white cottony patches known as soft exudates. These changes may not alter
your vision. But if the fluid or blood leakage occurs near the macula, the part of the retina
responsible for sharp, central vision, sight will be impaired. After 20 years, nearly all people with
type 1 diabetes will have developed retinopathy if blood sugar is not controlled (Nathan, 2004).
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Nerve damage, or neuropathy, from diabetes has widespread effects, and again, the
blame rests with abnormally high blood sugar levels. When nerve damage occurs, the network of
nerves that relays messages to and from different parts of the body slows down, sends the
wrong cues, or fails to work. Scientists aren’t certain why this happens, but they think the
damage may result when glucose attaches to or affects proteins in nerve cells, causing a chemical
imbalance inside the nerves or restricting the blood flow to the nerves (Nathan, 2004).
Nerve damage can cause changes in sensory perception, pain, or problems with
digestive, bladder, bowel, or sexual function. About 60%-70% of people with diabetes have
some signs of neuropathy that may be detectable only with a physical exam or special testing,
and a smaller percentage has more severe symptoms. Serious neuropathy, especially when
combined with vascular complications, can lead to foot ulcers and the loss of lower limbs
(Nathan, 2004).
Diabetes is the leading cause of kidney failure, accounting for about 40% of new cases;
most people with diabetes don’t develop this life-threatening condition. Kidneys filter toxins and
wastes from the bloodstream, flushing them out of the body through urine, while retaining
important proteins and other useful substances. This filtering work is done by glomeruli, a
delicate network of capillaries. But after prolonged exposure to high blood sugar, capillary
membranes thicken, and the glomeruli are damaged and distorted (Nathan, 2004).
Three out of four people with diabetes die from heart disease or stroke. While experts
don’t fully understand the causal relationship between diabetes and cardiovascular disease, it’s
clear that diabetes is often accompanied by various heart disease risk factors, such as high blood
pressure, high cholesterol, high triglycerides, and obesity. Diabetes is also associated with an
increased tendency for forming clots (Nathan, 2004).
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Strict control of blood glucose levels is highly important in a diabetic’s life to avoid or at
least help delay the development of such complications listed previously. It seems to be apparent
that diagnosis of any of those complications would severely compromise a diabetic’s quality of
life. This is why insulin in any way is helpful to stabilize the blood sugar levels.
Different types of diabetes can be controlled by different medications. For instance,
Type 2 diabetes can be controlled by diet, or it may take medication to help the body’s insulin
production work correctly. Later stages of Type 2 diabetes may require insulin for best control.
Type 1 diabetes however, requires insulin. It cannot be controlled any other way.
Insulin Analogs and Glargine
In the last decade, one of the most important innovations of blood glucose control was
the arrival of insulin analogs. Insulin analogs are versions of insulin that have been altered to
achieve greater control over blood glucose levels. Insulin lispro, the first insulin analog, was
introduced in August 1996 by Eli Lilly and Company under the brand name Humalog. Humalog
is a rapid-acting analog that works much more quickly than regular insulin and lasts only about
two hours. This makes it ideal for mealtime insulin injections. Compared to regular insulin,
which is supposed to be taken 30 to 45 minutes before meals, Humalog is taken within 15
minutes of eating, which adds flexibility and convenience to meal planning (JDRF, 2007).
Studies show that blood glucose levels two hours after meals are significantly lower in
people who use mealtime lispro compared with regular insulin. Another rapid-acting insulin
analog is called insulin aspart, manufactured by Novo-Nordisk. Like Humalog, Novolog is also a
fast-acting insulin to be used for bolus injection prior to meals. It was approved for marketing in
the U.S. by the Food and Drug Administration (FDA) in June 2000 (JDRF, 2007).
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In April 2000, the FDA granted marketing approval for insulin glargine or Lantus, which
is manufactured by Aventis Pharmaceuticals. Once injected, insulin glargine forms a precipitate,
which is absorbed very slowly and evenly into the bloodstream. Since its effects last nearly 24
hours with little variability and no peak action level, insulin glargine is an ideal “basal” or longacting insulin. A number of studies have compared the use of insulin glargine with that of the
most commonly used basal insulin, Neutral Protamine Hagedorn (NPH) (Rosenstock, et al.
2000). Neutral Protamine Hagedorn is a long-acting insulin, which generally is absorbed in the
blood over 5-6 hours. Results show, however, that regimens using insulin glargine offer blood
glucose control that is at least as good as and sometimes better than that seen with NPH insulin,
and it produced fewer episodes of hypoglycemia and less weight gain (JDRF, 2007).
Today, there are many new devices, such as the insulin pump, that can help avoid the
rigid rules and loss of freedom that used to be associated with diabetes. The rigid rules of a
diabetic’s life used to consist of exact meal timing to make it possible for insulin regimens to be
administered at the proper time. Now, the pump seemingly offers a great expansion of freedom
to diabetics by allowing exercise, with less risk of hypoglycemia and better glucose control by
learning how to carbohydrate count. Carbohydrate counting is an effective way to control insulin
regimens by means of giving only enough insulin to cover the grams of carbohydrate ingested.
With an insulin pump, you simply add up your carbohydrates ingested, and insert the number
into the pump—just like a calculator. The pump then figures out, based on your programmed
ratio, how much insulin is needed to cover your carbohydrates. If you are an active person with
diabetes, an insulin pump may be a good tool for living a more active and flexible life. The pump
is a reliable way to deliver insulin and to give people with diabetes more freedom in their daily
activities (Google Image Database).
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Insulin Pump
Insulin pumps are small devices, about the size of a pager. One or more microprocessors
control the rate and timing of insulin delivery. The first pump delivered both glucagon and
insulin. It was developed in 1963. This pump is shown in Figure 1. The next system invented
was called The AS2C and came out around 1977. A number of people living with diabetes used
this. The next device for insulin delivery was the AutoSyringe AS*6C, which was invented in
1980. It was able to infuse only diluted U-40 insulin at one basal rate. A glucose-controlled
insulin infusion system called the BioStar was invented in the 1980s and functioned as an
artificial pancreas. The MiniMed was released in the 1990s and is still worn by many people
today. The MiniMed is shown in Figure 1. An insulin pump is often worn on the user’s belt,
slipped inside a pocket, attached to the inside of a dress or undergarment, or worn on an elastic
band attached to the user’s arm or thigh (Google Image Database).

Figure 1. Insulin Pumps (Bode, Tamborlane, Davidson, 2002; Google Image Database)
Insulin pumps use quick acting insulin, such as Humalog, Regular, or Velosulin. Insulin
is delivered continuously through a needle inserted in the body, which is connected by a very
thin tube to the pump at the other end. The tube and needle are referred to as an “infusion set.”
Long acting insulin, such as NPH or UltraLente, is not used in insulin pumps (Google Image
Database).
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The pump is programmed to deliver a constant background rate of insulin called a basal
rate, which may change at various times during the day, to closely match the individual’s needs.
Typically, the basal rate does not need to be changed often, once the person’s blood glucose
patterns are known. There may be some variation due to changing sleep / wake schedules or
monthly hormonal changes. These changes can be accommodated quite easily with the pump
and therefore achieve better blood sugar control than insulin injections (Google Image
Database).
A dose of insulin called a “bolus” is programmed to meet the requirements of food
intake. This amount of insulin is usually calculated based on the amount of carbohydrates
contained in the meal or snack. A bolus can also be programmed to correct high blood glucose
readings. The amount of the bolus in these situations is based on how much a given amount of
insulin will lower the person’s blood glucose level (Google Image Database).
Insulin pumps have made a breakthrough over the last decade. The graph below (Figure
2) suggests that the number of insulin pump users is steadily increasing over the years.

Figure 2. Number of patients using subcutaneous insulin infusion pumps in United States
by year (Bode, Tamborlane, Davidson, 2002)
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Insulin Pump Advantages
Continuous subcutaneous insulin infusion (CSII) is used in selected type 1 diabetic
subjects to achieve strict blood glucose control. A quarter of a century after its introduction,
world-wide use of CSII is increasing (Bliss, 1982). Limited evidence shows that this increase is
due to the effectiveness of diabetes control by pump therapy compared with modern intensified
insulin injection regimens and concern about possible complications. A review of 13
randomized controlled trials showed that in most patients, mean blood glucose concentrations
and hemoglobin A1c percentages are either slightly lower or similar on CSII versus multiple
insulin injections, with the standardized mean difference being 0.44 (0.20 to 0.63) (Pickup,
Mattock, Kerry, 2002). However, hypoglycemia was markedly less frequent than during intensive
injection therapy. Ketoacidosis occurred at the same rate. Nocturnal glycemic control is
improved with insulin pumps; automatic basal rate changes on the pump help to minimize the
pre-breakfast blood glucose increases caused by hormonal elevations in the body known as the
“dawn phenomenon” (Nabhan, et al, 2006).
An increase in the blood sugar level between approximately 3:00 a.m. and the time a
person wakes is called the “dawn phenomenon.” The liver attempts to release just enough
glucose to replace what is being used, and insulin works as the messenger to tell the liver how
much is enough. But if there is not enough insulin (as in type 1 diabetes), or if there is adequate
insulin but it cannot communicate its messages to the liver (as in type 2 diabetes), the liver starts
to release glucose much too fast. The result of this is a rise in blood sugar levels. This is why
blood sugar levels can go up between the time a person goes to bed and the time he/she wakes
up, even though the individual has not eaten since supper (Pickup, 2006).
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Insulin Pump Disadvantages
Ketoacidosis is dangerously high levels of ketones. Ketones are acids that build up in the
blood as a result of fat and lean muscle breaking down. In order to move glucose from the
bloodstream into cells, insulin is required. If there is not enough insulin present, glucose does
not move into the cells and can build up in the bloodstream. When the body senses that cells are
not being fed, it will turn to fat stores and lean muscle mass as a source of energy. This happens
mainly when a person does not eat enough or there is not enough insulin in the blood stream.
Using fat for energy causes the body to make even more glucose. This is in addition to the
glucose already circulating in the bloodstream that is unable to enter cells due to the lack of
insulin. Blood glucose levels rise higher, more fat is burned as the body starves, and more
ketones are produced by the partial oxidation of fat. The kidneys try to cleanse the bloodstream
by excreting blood glucose and ketones through the process of urination. This is one of the
reason’s people with high blood glucose levels have to urinate frequently. But eventually the
kidneys become overworked and can no longer keep with the demand. Then, ketones and
glucose levels can build up to a level where organ damage, coma, and even death will occur. To
make matters even worse, the constant urination can dehydrate a person with diabetes.
Hypovolemia concentrates glucose and ketones in the blood making their effects even more
damaging (Joslin Diabetes Center Online, 2006). Ketones are thus an important warning sign
that a person’s diabetes may be out of control or that they are getting sick (ADA, 2006).
Most pump users will agree that the insulin pump’s advantages far outweigh the
disadvantages. However, it is important to recognize the disadvantages before initiating insulin
pump therapy. Use of the insulin pump may cause weight gain; it can be expensive without help
from insurance providers; it can be bothersome since the pump is attached to the body most of
the time; and initiation of the pump can require a hospital stay or a full day at an outpatient
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center to be trained; and if the pump’s catheter comes out from the body site (abdomen, upper
buttocks, upper thigh, or the triceps area of the arm) unbeknownst to the patient, diabetic
ketoacidosis can occur from lack of insulin infusion (ADA, 2006). Catheter sites generally used
are shown in Figure 3.

Figure 3. Catheter Example (Diabetes Forecast, 2006; Google Image Database)
Transitioning to the Insulin Pump
Some studies suggest an increased risk of diabetic ketoacidosis (DKA) on CSII
compared to injections whereas others show a reduction in DKA rates. Similarly, glycemic
control has been reported to improve or remain unchanged. Most studies, however, concur that
episodes of severe hypoglycemia appear to decrease while on CSII (Pickup, Keen, 2002).
A study completed by Riley Hospital in Indianapolis, Indiana, documented the initial
transition onto the insulin pump in children. The following variables were measured: control of
diabetes, number of injections daily prior to pump use, type of insulin used and history of
compliance with doctor recommendations regarding blood glucose control, and, last, diabetes
camp attendance (Pickup, Keen, 2002).
Before initiation of pump therapy, all families and patients attended a half-day education
session, during which insulin types, insulin adjustment, and carbohydrate counting were
reviewed. Families that had not previously used carbohydrate/insulin ratios or corrective doses
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began using these techniques after the education sessions. At the time of pump therapy
initiation, all patients held their morning dose of long acting insulin, began using their pump by
late morning, and remained through the afternoon for a second education session with a nurse
educator during which patients and families were taught the mechanics of pump use. For the
first 10 days, families were asked to check their child’s blood sugar at least eight times per day,
with tests before meals, before snacks, at midnight, and at 3 a.m. Families were also asked to
change infusion sets every 3 days (Pickup, Keen, 2002). Infusion sets are the site at which the
insulin pump is placed. It should be changed every 3 days to avoid infection and irritation of the
area of skin at which it is placed. Shown below is a picture of a “site.” This is a bandage-like
patch that contains the catheter as discussed above. This patch is shown below in Figure 4. The
catheter is the way the insulin moves from the insulin pump to just inside the body’s
subcutaneous fat layer before being up taken by the blood stream to reach the cells for use. The
site is placed on one of these parts of the body shown in Figure 4. At each 3-day interval, the site
should move to a new area to avoid creation of scar tissue.

Figure 4. Infusion Sites (Medtronic Online, 2006; Diabetes Forecast, 2006)
This study concluded that “Average HbA1c prior to pump start was 8.7 ± 0.9%. By 6
months post-CSII start, average HbA1c dropped to 8.1 ± 0.9% and then rose to 8.2 ± 0.8% at
12 months. At the time of the last available follow-up after a mean duration of pump therapy of
2.4 ± 0.8 years, HbA1c was 8.3 ± 0.6%. As of May 14, 2006, roughly two and half years after the
study initiated, 46 patients (18 boys and 28 girls) were in better control than the initial average,
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with an average HbA1c of 7.8 ± 0.4% (range, 7.0–9.0%) and 47 (17 boys and 30 girls) were in
poor control with an average HbA1c of 8.7 ± 0.6% (range, 8.0–11.0%)” (Pickup, Keen, 2002).
Insulin pump therapy offers a constant rate of insulin that is most closely mimicked by
an insulin glargine such as Lantus. Lantus offers a “basal-like” background rate of insulin going
into the body for 24 hours. A basal rate is a constant rate of insulin being administered to the
body in a small dose that is delivered continuously each hour. The basal rate usually makes up
40 to 50 % of a typical day’s insulin requirements. Most pump users have more than a single
basal rate during the day. The basal rate can be adjusted up or down, usually in 0.1 unit
increments, during periods of decreased (i.e. exercise) or increased (i.e. sick days, stress) insulin
requirements. The basal rate should keep the blood glucose within the desired range (70120mg/dL) between meals and overnight. If the basal rate is set correctly, the pump user should
be able to skip or delay meals without resulting high or low blood glucose (Medtronic Online,
2006). Although it was not documented, the improvement in glycemic control with younger
patients may pertain to more parental supervision and support while on CSII therapy (Pickup,
Keen, 2002).
Young children may benefit from insulin pump use the most due to the fact that
controlled diabetes from an earlier age decreases future complications that are associated with
uncontrolled glucose levels over many years of life. The DeVos Children’s Hospital in Grand
Rapids, Michigan, evaluated the safety and efficacy of CSII in children aged 2-7 years in a
retrospective study (Berhe, et al, 2005). Data were collected from chart review over 2 years.
Patients were on NPH + Humalog at least one year prior to CSII initiation. The results of the
study showed that the total insulin requirement was higher during twice-a-day injections than to
CSII. Also, the average fasting blood sugar was lower in pump therapy, severe hypoglycemic
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episodes were higher before pump therapy, and Hemoglobin A1c levels were lower after CSII
initiation (Berhe, et, al, 2005).
The study concluded that CSII therapy is safe and effective in young children with type 1
diabetes and is a superior alternative to twice daily insulin regimens (Berhe, et al, 2005). Insulin
pump therapy has been successful in adolescents while its use has been limited in young
children. Adults are able to be successful on the pump. However, limited studies have been
completed to show the advantages of pump use.
Adults and Insulin Pump Therapy
At the Atlanta Diabetes Associates, adults and adolescents on the insulin pump have
been investigated. This clinic used its patients for this study. The following were analyzed for
the study: the patients’ blood glucose log books, insulin doses, if they counted carbohydrates
versus an undefined diet, and whether they used insulin lispro or regular insulin. Among 413
adult patients with type 1 diabetes who used a pump, the average HbA1c value decreased from
8.3% to 7.5% over a mean of 3 years (normal value, <6.1%). Among 50 adolescent patients who
used CSII for a mean of 3.5+3.9 years, a significant decline in the average HbA1c level was
observed, from 9.6% before initiation of pump therapy to 8.3% after initiation of pump therapy
(Bode, Tamborlane, Davidson, 2002).
Analysis of patients during routine follow-up visits identified several factors key to
successful treatment with insulin pumps. The most important was frequency of blood glucose
monitoring. It was found that patients who monitored blood glucose levels three or more times
a day had a lower average HbA1c level than patients who monitored levels once or twice daily
(7.2% versus 8%). Of the 106 patients who stated that they monitored blood glucose levels five
or more times a day, 66 (62%) had an average HbA1c level of less than 7%. Each additional
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blood glucose measurement obtained daily corresponded to a 0.2% reduction in HbA1c (Bode,
Tamborlane, Davidson, 2002).
Patients who use pump therapy would seem to be at greater risk for the rapid
development of diabetic ketoacidosis than those who use insulin injections. This risk comes
because some insulin pump users forget or completely eliminate testing blood sugars, causing
frequent fluctuations in the blood sugar. However, it was observed in this study that there was a
reduction in ketoacidosis rates in both adolescent and adult groups. This reduction was achieved
through patient education on how to treat high blood glucose levels. Patients were instructed to
give themselves a manual subcutaneous insulin injection if ketone bodies were present in the
urine or if blood glucose levels were greater than 250 mg/dL for two consecutive readings.
They were then also told to change their infusion set to be sure that there were no occlusions in
the tubing or catheter (Bode, Tamborlane, Davidson, 2002).
Summary
Insulin pumps have made a breakthrough in the past decade. The 21st century continues
to show promise in eliminating harmful long term complications with diabetes. Most studies
have been based on child and adolescent insulin pump therapy. There have been only a limited
number of studies concluded in adults. This study therefore compared adult intensive insulin
pump therapy vs. multiple injection therapy use and its effects on the quality of life and overall
improvement of glucose control of type 1 insulin dependent adults.
Rationale for the Study
Insulin is the only method of controlling Type 1 diabetes. Insulin can be delivered either
by multiple injection therapy or by insulin pump. There is not adequate data available comparing
intensive insulin pump therapy and multiple insulin injection therapy to treat diabetes. The
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pump seemingly helps tighten the control of blood glucose, thus decreasing the risk of
complications with diabetes. This research was therefore undertaken to investigate which tool
for diabetes control, intensive insulin pump therapy or multiple insulin injections, has the
greatest effect on the quality of life of a diabetic by means of lowering hemoglobin A1C levels (3
month average of blood sugar levels), increasing frequency of exercise, and maintaining
consistent meal patterns.
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Chapter 3
Research Methodology
Overview of Study
The primary purpose of this research study was to analyze the effects of intensive insulin
pump therapy vs. multiple insulin injection therapy on the quality of life in adult type 1 insulin
dependent diabetics by means of lowering hemoglobin A1C levels, increasing exercise, and
ingesting consistent meals daily. Insulin dependent type 2 diabetics were eliminated from the
study due to the fact that most also rely on oral diabetic agents to control their glycemic levels.
The groups consisted of 30-45 year old adult diabetics in an endocrinology and diabetes
center in a suburban area of Port Huron, Michigan. The sample was made up of 20 subjects
(n=20); the multiple injection therapy group (control) contained seven (7) patients, and the
intensive insulin pump therapy group (experimental) consisted of thirteen (13) patients.
First, the endocrinologist obtained consent from the patient regarding participation in
the study (Appendix A). Once consent was given by the patient, the researcher contacted the
patient by phone and administered a telephone survey (Appendix B or C). At the completion of
the survey, the patient’s chart was studied to examine hemoglobin A1C. Each subject was
assigned a number to provide anonymity and the information was recorded. Participants who
chose to see the results of the study were notified by mail.
Hypothesis
The following hypothesis was tested in this research: There is a significant difference in
adult diabetics’ overall health and quality of life when multiple insulin injections are used
compared to intensive insulin pump therapy.
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Description of Sample
The sample used in this research study was a randomized group that consisted of a total
of 20 subjects (n=20). The sample was derived from a suburban endocrinology and diabetes
center. This office is located in an established community in Port Huron, Michigan. The subjects
ranged in age from 30-45 years. Seven (7) of the subjects were currently using multiple insulin
injection therapy (control), and thirteen (13) of the subjects were currently on intensive insulin
pump therapy (experimental).
Research Study Design
A retrospective cohort study design was used. A pilot study was conducted initially with
six subjects (n=6) to validate the survey tools being used in the study. Once the pilot study was
completed with no revisions to the surveys, consent forms (Appendix A) were mailed to the
study participants. Once signed, participants returned the informed consent forms to
endocrinologist Sushma Reddy, MD. The researcher then telephoned subjects and administered
a short survey regarding exercise, meal consistency, and quality of life. Daily meal consistency,
exercise, and quality of life opinions were used to compare lifestyles of those using the insulin
pump to subjects using insulin injections. Once the surveys were completed, the researcher
obtained information from patients’ charts regarding hemoglobin A1C levels.
Following the completion of the surveys and chart observations, the following
comparisons were made:




Analysis of subjects’ charted HbA1C were evaluated using a 2-mean hypothesis
test to determine if pump users’ HbA1C was less than that of multiple injection
therapy subjects.
Analysis of subjects’ self-reported exercise habits using a 2-sample hypothesis
test, to determine if pump users’ exercise was greater than the exercise of
multiple injection therapy subjects.
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Analysis of subjects’ self-reported dietary intake, using a 2-proportion
hypothesis test, to determine if pump users intake is closer to the recommended
3 meals and 3 snacks a day than the multiple injection therapy subjects.
Analysis of subjects’ self-reported quality of life, using a 2-proportion hypothesis
test, to determine if pump users feel they are in better health regarding their
diabetes than the subjects using multiple injection therapy.

This study was approved by Eastern Michigan University’s Human Subjects Review
Committee prior to study inception (Appendix D). Patients were kept completely anonymous
and their responses were confidential.
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Chapter 4
Results and Conclusions
Results
After the analysis, patients’ hemoglobin A1C levels, exercise patterns, meal patterns
frequency, and quality of life revealed the following: Hemoglobin A1C concentrations were
obtained from charts of patients who received multiple insulin injections or insulin pump
therapy once consent was received. The data (Table 1) were analyzed using a 2-sample
hypothesis test to determine if insulin pump users’ hemoglobin A1C concentrations were lower
than those of insulin injection users. The researcher accepted the null hypothesis and rejected
the alternative that at the p=.05 significance level, there was no statistical evidence to support
the claim that pump users had lower hemoglobin A1C than those using insulin injections.
Individual values for hemoglobin A1C for injection users and Pump therapy users (%) are
depicted in Table 1. Average hemoglobin A1C’s are illustrated in Figure 5. Multiple injection
therapy averaged a hemoglobin A1C level of 6.8% compared to intensive insulin pump therapy,
which averaged 7.9%.
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Table 1. Hemoglobin A1C Results
Hemoglobin A1C values in patients who used insulin injections (n=7) versus patients who used insulin pump
therapy (n=13). There is no statistical evidence to support pump users HbA1C is less than that of injection
users.
Insulin
Injection
Results

Insulin Pump
Therapy
Results

6.5

7.9

5.5

7.8

6.7

6.9

8.0

8.1

8.2

7.9

6.6

8.0

6.6

8.0
8.5
7.6
8.2
9.2
6.8
7.8

Hemoglobin A1C Averages
Intensive Insulin
Pump Therapy
(Experimental
Group)

1

Multiple Injection
Therapy (Control
Group)
6

7

8

Figure 5. Hemoglobin A1C Averages
During the survey, participants were asked how many days a week they exercised and
what types of activities they were involved in. The data (Table 2) were analyzed using a 2-sample
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hypothesis test to determine if pump users exercised more days in a week than multiple injection
therapy subjects. The null hypothesis was rejected and the alternative hypothesis was accepted at
the p=.05 significance level. The results revealed that insulin pump users do exercise more than
insulin injection users. Results are depicted in Table 2. Multiple insulin injection therapy
subjects’ weekly average exercise was 0.42 days, compared to intensive insulin pump therapy
subjects who reported exercising for 2.1 days on an average every week.

Table 2. Exercise Results
Exercise days per week reported by insulin injection users (n=7) versus insulin pump users (n=13). Results
revealed that insulin pump users exercise more than insulin injection users.
Insulin
Injection
Results

Insulin
Pump
Therapy
Results

0

3

0

0

0

3

0

0

0

7

1

0

2

0
0
0
1
5
2
7
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Exercise Weekly Averages

Intensive Insulin
Pump Therapy
(Experimental
Group)

1

0

1

2

3

Multiple Injection
Therapy (Control
Group)

Number of Days

Figure 6. Exercise Weekly Averages
Consuming regular meals is vital for diabetic patients. The next variable tested whether
diabetic patients on the pump consumed more frequent meals compared with those receiving
multiple insulin injections. A 2-proportion hypothesis test was used to compare whether more
pump users consume 3 meals and 3 snacks a day compared to insulin injection users. Data
(Table 3) analysis resulted in the rejection of the null hypothesis and acceptance of the
alternative at the p=.05 significance level concluding that pump users are more likely to ingest 3
meals and 3 snacks a day than insulin injections users. Results are represented in Figure 7. The
blue portion of the chart represents the percentage of those who consistently consumed 3
meals/3 snacks a day, and the red portion shows the percentage of those who did not. Fiftythree point nine percent of subjects on pump therapy consumed at least 3 meals/3 snacks every
day, whereas only 42.7% of injection users responded that they did so.
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Table 3. Meal Consistency Results
Consumption of 3 meals /3 snacks per day reported by insulin injection users (n=7) versus insulin pump users
(n=13). Data suggested that Insulin pump users are more likely than insulin injection users to eat 3 meals /3
snacks per day.
Insulin
Injection
Results

Insulin Pump
Therapy
Results

No

Yes

No

Yes

Yes

No

Yes

No

No

No

No

No

Yes

No
Yes
Yes
No
Yes
Yes
Yes

Meal Consistency (3 Meals/3 Snacks)

% Per Day

100.00%
90.00%
80.00%
70.00%
60.00%
50.00%
40.00%
30.00%
20.00%
10.00%

46.15%

57.14%
No
Yes

53.85%

42.86%

0.00%

Pump Therapy
(Experimental)

Injection Therapy
(Control)

Figure 7. Meal Consistency
Last, overall quality of life of participants who used the pump versus those who received
insulin injections was subjectively assessed and compared. Each subject was asked a question
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pertaining to his/her opinion of his/her overall quality of life related to his/her diabetes. The
subjects were offered only two answers: yes for good health or no for poor health. Analysis of
the data (Table 4), using a 2-proportion hypothesis test, at the p=.05 significance level, rejected
the null hypothesis and accepted the alternative that pump users feel that they are in better
health than insulin injection users. Results are illustrated in Figure 8 below. The blue portion of
the chart represents the percentage of subjects who felt they had a high quality of life, and the
red portion represents the percentage of subjects who felt they had a lower quality of life.
Ninety-two percent of pump users thought that they were in good health compared to 71 % of
participants who received multiple insulin injections.
Table 4. Quality of Life Results
Quality of Life opinions reported by insulin injection users (n=7) versus insulin pump users (n=13). It was
determined that Insulin pump users feel they are in better health than insulin injection users.
Insulin
Injection
Results

Insulin Pump
Therapy
Results

Yes

Yes

No

Yes

No

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes
No
Yes
Yes
Yes
Yes
Yes
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Quality of Life Opinion

100.00%

7.69%
28.57%

90.00%
80.00%
70.00%
60.00%
50.00%

No

92.31%
71.43%

40.00%

Yes

30.00%
20.00%
10.00%
0.00%
Pump Therapy
(Experimental)

Injection Therapy (Control)

Figure 8. Quality of Life Opinion
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Chapter 5
Discussion
Discussion
The four parameters evaluated in this study in type 1 diabetic patients who received
insulin either via multiple injections or via a pump were hemoglobin A1 concentrations to reflect
long term glycemic control, frequency of weekly exercise, consumption of 3 meals/snacks daily
and self-reported opinions about quality of life. Compared to patients receiving multiple
injections, patients using the insulin pump did not have lower hemoglobin A1C concentrations,
suggesting that pump users did not necessarily have an improved regulation of their blood sugar.
However, pump users reported that they exercised better, consumed more frequent meals, and
generally felt that they had a better quality of life than patients receiving insulin injections.
Multiple injection therapy patients’ hemoglobin A1C levels were significantly lower than
insulin pump users. An A1C level gives patients an assessment of average blood glucose levels
for the past 2-3 months. When blood sugar is unregulated, the excess glucose enters the red
blood cell and glycates with hemoglobin. The higher the levels of excess glucose in the blood,
more hemoglobin gets glycated and the higher the levels of HbA1C. Since the lifespan of a red
blood cell is about 120 days, HbA1c levels in the blood reflect blood sugar concentrations for
the last 3-4 months. The American Diabetes Association recommends an A1C level of < 7 % in
diabetic patients following treatment, referenced to a non-diabetic range of 4.0–6.0%. Earlier
studies described in Chapter 2 of this thesis suggested that patients using the pump did improve
their glycemic control. It is important to recognize that limited numbers of patients in this study
may have impacted the results. Most physicians these days encourage patients on insulin to
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switch to using a pump. It was thus difficult to locate patients who still utilized multiple insulin
injections. Thus with the control sample size being limited for multiple injection therapy, it is
possible that further studies may reveal that multiple injection or pump therapy are equally
effective for controlling blood sugar. Nevertheless, only two of thirteen patients evaluated using
the pump had HbA1C values that were below 7.0% whereas five of the seven patients tested on
the pump had HbA1C values that were below 7.0%. It is pertinent to note here that all these
patients were screened at the same clinic. The likelihood of high hemoglobin A1C levels in
pump users may be due to erratic scheduling, diet inconsistencies (time frame changes), and
perception of more flexibility to eat high carbohydrate foods without the problem of covering
with insulin injections. Another possibility behind insulin injection users HbA1C being lower
than pump users could be the fact that injection users may exhibit more hypoglycemic reactions
than insulin pump users. Since pump users described their quality of life as being better, it is also
possible that they get lulled into believing that they need not keep an eye on their diets regularly.
And although they reported that they consumed regular meals, this study did not compare or
take into account the quality or nutritive content of the diet consumed. Thus pump users could
be consuming more carbohydrates and/or simple sugars, resulting in their inferior values for
HbA1C. Our results thus indicate that although there may be improvement in regulating blood
sugar in pump users, patients using multiple injections fared better and had a much superior
glycemic control.
It was found that insulin pump subjects were more likely to exercise than multiple
injection therapy users. Reasons given by participants varied; however, most often scheduling
conflicts were the reason behind lack of exercise. Interestingly, in either group hypoglycemia was
not of concern as a barrier to exercise.
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Participants were questioned about their daily meal planning. It was found that insulin
pump users were more likely to consume 3 meals and 3 snacks a day (than multiple injection
therapy subjects.) Patients were not questioned as to why their meals were not consistent.
However, injection participants were asked if they count carbohydrates, and three out of four
participants answered yes. Likewise, the insulin pump participants were asked if they
carbohydrate counted prior to the insulin pump, and seven out of the thirteen participants
answered no. Thus as stated before, pump users could perceive that being on the pump
rendered them the flexibility to not watch their diets as keenly as non-pump users.
The last feature evaluated was the patients’ opinion of their quality of life. Intensive
insulin pump subjects’ perception of their lives were superior to those on multiple injection
therapies. Pump users’ reasons for feeling they have a better quality of life was better control
(according to them) over their blood sugar readings, freedom—not having to worry about
injecting before meals —and a more “normal” life. It should also be stated that all thirteen
pump users questioned regarding whether they would recommend the insulin pump to injection
users stated yes.
Thus although diabetic patients exercised more frequently, regulated their meal intake,
and professed that they were in better health while using the pump, in reality their glycemic
control was not superior to patients who used multiple insulin injections.
Limitations
In this study there were two limitations that were noted. The first limitation was that the
age group was too limited for insulin injection therapy. By the ages 30-45 years, it was found that
most type 1 insulin dependent diabetics prefer pump therapy for easier control.

32

The second limitation was sample size. The goal was to recruit 40 subjects: 20 multiple injection
therapy and 20 insulin pump users. Once consent forms were received it was discovered that
limited participants were available at the particular endocrinology and diabetes center. A more
expansive sample may have shown a better comparison of the two groups studied.
Suggestions for Change
If this research were to be replicated, it would be recommended that the age group be
expanded by five years on both ends, changing it from 30-45 to 25-50 years. This would result in
an increase of the sample size.
Another aspect that could increase sample size would be to include type 2 insulin
dependent diabetics and factor in the use of oral agents. Type 2 diabetics on insulin weren’t able
to be used because they also were receiving oral agents along with insulin for best control, and
the results may have been skewed had these patients been used in the data.
The next change would be the time frame. If more time were allotted to the project,
surveys could be completed in person. This survey was completed entirely over the telephone.
The participants spoke with the researcher for roughly 10-15 minutes. However, it is thought
that with an in-person survey, participants may be more likely to share more personal
information than with a researcher over the telephone.
Last, incorporating additional endocrinologists throughout the mid-Michigan area and
possibly over the country into the study, as opposed to one suburban location, would help to
increase the sample size. This may also help contribute to different ethnicities and populations.
Conclusions and Significance
The overall conclusion of this study was that the hypothesis that “there is a significant
improvement in adult diabetics’ overall health and quality of life when using intensive pump
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therapy compared to multiple insulin injections” was disproved. Although three out of the four
parameters studied – frequency of exercise, consumption of regular meals/snacks, and overall
self-reported quality of life - were better in pump users, hemoglobin A1C, the only measurable
outcome that correctly reflects glycemic control, was not enhanced in patients on the pump
compared to patients receiving multiple insulin injections. Thus, although patients on the insulin
pump therapy perceived that their health was improved, this study concludes that intensive
pump therapy may not be a better treatment than multiple insulin injections.
Health care providers, particularly physicians and dietitians who treat diabetic patients,
should not become complacent with diabetic patients receiving insulin pump therapy. They
should recognize this problem with glycemic control in insulin pump users and counsel them to
watch their diets and frequently monitor their blood sugar. This study thus has important
implications in diabetes care and management.
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Appendix A
Insulin Pump Study
Consent Form
The purpose of this study is to determine whether continuous subcutaneous insulin infusion
(insulin pump) is a better way of controlling diabetes than insulin injections. This will show if it
is significant in helping to improve the quality of life in diabetics by means of improving
hemoglobin A1c levels, diet and exercise and possibly decrease risk of long term complications
associated with diabetes.
The research undertaken in this study will investigate the effects of intensive insulin pump
therapy vs. multiple injection therapy on the quality of life in adult insulin dependent diabetics by
means of lowering hemoglobin A1c levels, increasing exercise due to decreased fear of hyper or
hypo-glycemia and healthier eating. The study will focus on five variables:
1.
2.
3.
4.
5.

Hemoglobin A1c level (below 7%).
Weight changes (Average over the past year).
Exercise (3 times a week for 30 minutes or more).
Diet (Eating 3 meals and 3 snacks daily).
Quality of Life (Subject opinion).

You can help in this project by allowing research to be concluded through use of your medical
charts and also complete a 10-15 minute telephone survey with the investigator. Participation in
this project is strictly voluntary. You are free to withdraw your participation at any time.
When the telephone survey is complete, your name will not be attached to the transcript. A
number will be assigned to your particular case, protecting your identity. This informed consent
form, with your name, will not be matched with the data, and your participation will be kept
confidential.
Any questions or concerns regarding the study, survey or procedures of this research are to be
directed to Dr. Stephen Sonstein, chair Human Subjects review committee of the College of
Health and Human Services at Eastern Michigan University, Ypsilanti, Mi-48197. He can be
reached at (734) 487-1238 or at Stephen.sonstein@emich.edu or Dr. Anahita Mistry at phone
number (734)-487-5079 or through email amistry@emich.edu.
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Appendix A
Insulin Pump Study
Consent Form
It is my right to withdraw at anytime from completion of the study without penalty. I have read
all of the above information regarding this study. The procedures and requirements have been
explained to me and I understand them. I freely and voluntarily consent to be a participant. For
my records, I have been provided with a copy of this consent form.
I understand that my personal medical charts will be used but also understand that the
information that I give will be held in the strictest confidence and that my responses will be kept
separate from my identifying information.
____________________________________________________
Name

____________
Date

I elect to have the results of this study mailed to me through standard mail. ______ ______
Yes
No
If yes, please provide your mailing information below:
Street Address
City, State, Zip Code

Any questions regarding the study results, survey or procedures of this research are to be
directed to Dr. Anahita Mistry at phone number (734)-487-5079 or through email
amistry@emich.edu.
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Appendix B
Insulin Pump Study
Telephone Survey
Please answer the following questions about you and your insulin pump history.
All information will be kept confidential.
Exercise
Please answer the following questions:
How many days a week do you exercise 30 minutes or more?

1 2 3 4 5 6 7

What types of activities are you involved in?
If your activity improved after getting on the insulin pump, please explain why you think this
may be (i.e. less fear of hypoglycemia (low blood sugar)):
Diet
Please answer the following to the best of your knowledge.
Did you use carbohydrate counting prior to insulin pump use?YesNo
Do you think carbohydrate counting after insulin pump initiation
has improved your diet?

YesNo

Do you find any difficulties in carbohydrate counting? Please explain:
Diet Diary
Please record everything you ate for 1 week day and 1 weekend day at every meal and snack hour to the best of
your ability.
Weekday
Breakfast:
Snack:
Lunch:
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Snack:
Dinner:
Snack:
Weekend day
Breakfast:
Snack:
Lunch:
Snack:
Dinner:
Snack:
Quality of Life
Please answer the following:
Overall, in your opinion, do you think your health has improved while using the pump
compared to insulin injection regimens?
YesNoNo change
Would you encourage others to use an insulin pump if recommended by their physician?
YesNoNo opinion
Please explain why you feel the pump has or has not increased the quality of your life and health:
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Appendix C
Insulin Injection Study
Telephone Survey
Please answer the following questions about you and your insulin injection history.
All information will be kept confidential.
Exercise
Please answer the following questions:
How many days a week do you exercise 30 minutes or more?
What types of activities are you involved in?

1 2 3 4 5 6 7

Diet
Please answer the following to the best of your knowledge.
Do you use carbohydrate counting? YesNo
If you answered No, to the above question, do you think carbohydrate counting could improve
your diet?
YesNo
If you use carbohydrate counting, do you find any difficulties in carbohydrate counting? Please
explain:
Diet Diary
Please record everything you ate for 1 week day and 1 weekend day at every meal and snack hour to the best of
your ability.
Weekday
Breakfast:
Snack:
Lunch:
Snack:
Dinner:
Snack:
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Weekend day
Breakfast:
Snack:
Lunch:
Snack:
Dinner:
Snack:
Quality of Life
Please answer the following:
Overall, in your opinion, do you think you are in good health regarding your diabetes?
YesNoNo change
Would you consider the use of an intensive insulin pump therapy if recommended by your
physician?
YesNoNo opinion
Please explain why you feel the pump may or may not increased the quality of your life and
health:
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Appendix D
Approval from Human Subjects Committee
Eastern Michigan University

January 16, 2007

Katie Reynolds
c/o Anahita Mistry, PhD
School of Health Sciences
Eastern Michigan University
Ypsilanti, MI 48197
Dear Ms. Reynolds,
The CHHS Human Subject Review Committee has reviewed your request entitled
“Quality Of Life Of Diabetic Subjects Using The Pump To Deliver Insulin Compared
With Those Taking Insulin Injections” submitted on January 8, 2007. The Committee
unanimously agreed that it meets the Minimal Risk standards and that the study can be
initiated.
The Committee may request further approval if secondary analysis of the data is
conducted.
Sincerely,

Stephen A. Sonstein, PhD
Chair, CHHS Human Subjects Review Committee

Dean, College of Health and Human Services  301 Marshall Building  Ypsilanti, Michigan 48197
Phone: 734.487.0077 FAX: 734.484.0038
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Appendix E
List of Abbreviations
HbA1C: Hemoglobin A1C
ADA: American Diabetes Association
JDRF: Juvenile Diabetes Research Foundation
NPH: Neutral Protamine Hagedorn
CSII: Continuous Subcutaneous Insulin Infusion
FDA: Food and Drug Administration
DKA: Diabetic Ketoacidosis
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